Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228064 | 0.94 | ESR1 (0.36) | ESR1ESR2CCKBRCA1CA2 | |
| SCHEMBL224522 | 0.91 | ESR1 (0.37) | ESR1ESR2CA1CA2ACHE | |
| SCHEMBL15876398 | 0.88 | ESR1 (0.33) | ESR1ESR2 | |
| SCHEMBL227459 | 0.86 | ESR1 (0.43) | ESR1ESR2CA1CA2ACHE | |
| SCHEMBL228741 | 0.86 | ESR1 (0.43) | ESR1ESR2CA1CA2ACHE | |
| SCHEMBL228323 | 0.85 | ESR1 (0.43) | ESR1ESR2CCKBRCA1CA2 | |
| SCHEMBL225408 | 0.83 | ESR1 (0.41) | ESR1ESR2CA1CA2ACHE | |
| SCHEMBL2741794 | 0.83 | ESR1 (0.37) | ESR1ESR2CA1CA2ACHE | |
| SCHEMBL228839 | 0.81 | ESR1 (0.39) | ESR1ESR2CA1CA2ACHE | |
| SCHEMBL228838 | 0.81 | ESR1 (0.39) | ESR1ESR2CA1CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | RADIUS HEALTH, INC. | 2012-01-05 | — | — | US | disclosed |
| US-7960412-B2 | Selective estrogen receptor modulator | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004315-A1 | Selective Estrogen Receptor Modulator | ESR1, GPER1, ESR2 | ESR1 1/4885ESR2 3/4885CCKBR 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.